Table Of ContentGlobal
Pharmaceutical
Policy
Edited by Zaheer-Ud-Din Babar
Global Pharmaceutical Policy
Zaheer-Ud-Din Babar
Editor
Global
Pharmaceutical
Policy
Editor
Zaheer-Ud-Din Babar
Centre for Pharmaceutical Policy and Practice Research
University of Huddersfield
Huddersfield, UK
ISBN 978-981-15-2723-4 ISBN 978-981-15-2724-1 (eBook)
https://doi.org/10.1007/978-981-15-2724-1
© The Editor(s) (if applicable) and The Author(s) 2020
This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether
the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and trans-
mission or information storage and retrieval, electronic adaptation, computer software, or by similar or
dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specific statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
The publisher, the authors, and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or
the editors give a warranty, expressed or implied, with respect to the material contained herein or for any
errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional
claims in published maps and institutional affiliations.
Cover illustration: © imageBROKER / Alamy Stock Photo
This Palgrave Macmillan imprint is published by the registered company Springer Nature Singapore
Pte Ltd.
The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721,
Singapore
To Danyal
Preface
The pharmaceutical policy deals with access to safe, effective and “quality
use of medicines”. Around the globe, there are challenges in regard to
access to innovative treatments and the affordability of expensive medi-
cines. Also, “access to high-cost medicines”, “innovative biologicals and
vaccines” and the “issues related to medicines access, trade, and intellec-
tual property rights” are central to any pharmaceutical policy. However,
dealing with these issues and forming effective pharmaceutical policies
has played a central role in improving access to medicines.
The pandemics like COVID-19 have again put a major emphasis on
the need for newer innovative treatments and the availability of afford-
able vaccines. The national pharmaceutical policies have been effective in
eradicating diseases and in improving patients’ quality of life. However,
forming these policies is a complex challenge and requires a number of
capacity-building measures including good governance and legislation,
trained workforce and human expertise as well as a viable local pharma-
ceutical industry.
This book documents a number of pharmaceutical policy issues in the
form of synthesis, reviews, case studies as well as examples from a number
of low-, middle- and high-income countries. The major themes include
“medicines access”, “medicines use” and “medicines safety”.
“Access to medicines” being a major component of national medicine
policies has been discussed in great detail in the book. There are a number
vii
viii Preface
of chapters covering pricing, access, generics, biosimilars, access to vac-
cine and immunization, public participation in access to medicines as
well as access to cancer medicines. There are country case studies covering
access to medicines in Mexico, Ukraine, Russia and Kyrgyzstan. Medicines
pricing is the single most determining factor on access, and there is a
chapter covering new medicine pricing models. Similarly, generic medi-
cines play a vital role in promoting access and reducing costs. The chapter
on generics discusses in detail the impact of generic medicines policies on
global pharmaceutical policy.
There are also chapters on medicine safety, antibiotic use, antibiotics
resistance as well as on the importance of the pharmaceutical supply
chain. The book also includes chapters on pharmaceutical policy litera-
ture on Pakistan and China. There is also a series of editorials on
“Medicines access, use, and pharmaceutical health system”.
The book discusses global pharmaceutical policy from various angles,
including key factors impacting it as well as challenges it faces. The book
also narrates how different countries deal with it, and what makes a pol-
icy successful. I hope that the book would be useful for a wide range of
readers including students, researchers, academics and policymakers in
this field.
20 March 2020
Huddersfield, UK Zaheer-Ud-Din Babar
Contents
1 Medicines Safety in the Globalized Context 1
Rabia Hussain, Mohamed Azmi Hassali,
and Zaheer-Ud-Din Babar
2 Managing the Pharmaceutical Supply Chain—To
Sustainability and Beyond 29
Liz Breen, Marina Papalexi, and Ying Xie
3 Generic Medicines and Biosimilars: Impact on Global
Pharmaceutical Policy 53
Mohamed Izham Mohamed Ibrahim and Ahmed Awaisu
4 Global Access to Cancer Medicines 73
Hye-Young Kwon and Yujeong Kim
5 Medicines Pricing: Limitations of Existing Policies and
New Models 99
Sabine Vogler
ix
x Contents
6 P harmacy Practice and Policy Research in Pakistan: A
Review of Literature Between 2014 and 2019 139
Iram Malik, Muhammad Atif, Shane L. Scahill,
and Zaheer-Ud-Din Babar
7 P romoting Access to Cancer Medicines in Mexico: Seguro
Popular Key Policy Components 177
Daniela Moye-Holz, Anahí Dreser, Octavio Gómez-D antés,
and Veronika J. Wirtz
8 A ccess to Medicines: Case Studies from Russia and
Kyrgyzstan 223
Liliya Eugenevna Ziganshina, Chinara M. Razzakova,
Syed Shahzad Hasan, and Zaheer-Ud-Din Babar
9 A ccess and Use of Medicines in Ukraine 247
Grintsova Olga and Zaheer-Ud-Din Babar
10 Public Participation in Access to Medicines 261
Sofia Crisóstomo and Filipa Alves da Costa
11 Pharmaceutical Policy and Practice Research: A Review of
Studies in China 293
Caijun Yang, Amna Saeed, Khezar Hayat, Krizzia- Mae
Lambojon, Ali Hassan Gillani, and Yu Fang
12 A ccess to Vaccines and Immunization Programme 309
Suthira Taychakhoonavudh
13 Global Antibiotics Use and Resistance 331
Mamoon Aldeyab, José-María López-Lozano,
and Ian M. Gould
Contents xi
14 Medicines Access, Use and Pharmaceutical Health System
Issues: Reflections, Thoughts and Points to Consider 345
Zaheer-Ud-Din Babar and Shane L. Scahill
